The new technology assessment
Article Abstract:
Technology assessment refers to the evaluation of new medical technologies and treatments. This practice has become increasingly systematic and objective over time as methods of clinical research have evolved; the ultimate tool of technology assessment is now the randomized clinical trial. The most basic purpose of technology assessment is to evaluate the safety and efficacy of the treatment to assure that the potential benefits outweigh the possible risks. Recently, new dimensions have been added to the process; these include consideration of patient preference, effect on the quality of life, and costs versus benefits. The last consideration has received much attention because the need to contain the ever-rising cost of medical care. Both the federal government and private foundations have committed millions of dollars to technology assessment so that the most cost-effective treatments can be identified. While the value of technology assessment is evident, this practice is also threatening to some. Many physicians believe that ultimately the assessments will limit their autonomy to choose the treatments they consider best. Manufacturers of medical equipment and pharmaceuticals are concerned that technology assessment may inhibit efforts to develop new treatments. Yet it is clear that technology assessment is here to stay, and these groups must try to understand and effectively work with them. This article reviews the nature of technology assessment in medicine, the characteristics of a good assessment, and implications for physicians. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1990
User Contributions:
Comment about this article or add new information about this topic:
The price of growth in the medical-device industry
Article Abstract:
Boston Scientific outbid Johnson & Johnson to purchase Guidant Corporation, which happened to be substantially more than Boston Scientific's own market value of $20 billion. Boston Scientific will have to charge high prices for its devices in order to rationalize its purchase, which will be difficult due to Medicare's fiscal crisis and the increasingly unstable state of private health insurance.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Corporate treatment for the ills of academic medicine
Article Abstract:
American Academic Medical center's adopt a more corporate minded approach towards their business as they face newer challenges from a number hospital chains and medical services that specialize in high margin service. The best example of a corporate minded approach is the number of partnerships between different American Medical centers.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Diabetic nephropathy: an update. Treatment selection considerations for the hypertensive diabetic patient. Diabetic nephropathy: the internist's role
- Abstracts: Optimal etching time of glass ionomer cement for maximum bond of composite resin. The glass ionomer cement
- Abstracts: The risk of subsequent primary malignant disease after cancers of the colon and rectum: a nationwide cohort study
- Abstracts: Corrosive injury of the esophagus in children; failure of corticosteroid treatment reemphasizes prevention. A controlled trial of corticosteroids in children with corrosive injury of the esophagus